The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...
The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of ...
Colton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results